Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
暂无分享,去创建一个
Cheng Cheng | Dario Campana | Xueyuan Cao | Ching-Hon Pui | Yiping Fan | Stanley B Pounds | Deqing Pei | Wenjian Yang | J. Downing | M. Relling | Cheng Cheng | D. Campana | C. Pui | W. Evans | L. Treviño | Wenjian Yang | S. Hunger | C. Willman | M. Borowitz | D. Pei | G. Neale | M. Devidas | W. Carroll | S. Pounds | S. Davies | Jun J. Yang | W. Bowman | Yiping Fan | Xueyuan Cao | B. Camitta | Mary V Relling | James R Downing | Lisa R Treviño | Deborah French | Stephen P Hunger | William L Carroll | Meenakshi Devidas | Geoffrey Neale | William E Evans | Stella M Davies | Cheryl L Willman | D. French | Michael J Borowitz | W P Bowman | Jun J Yang | Bruce M Camitta | PhD Jun J. Yang | PhD Cheng Cheng | PhD Wenjian Yang | MS Deqing Pei | MS Xueyuan Cao | PhD Yiping Fan | PhD Stanley B. Pounds | PhD Geoffrey Neale | PhD Lisa R. Trevin˜o | PhD Deborah French | MD Dario Campana | PhD James R. Downing | MD William E. Evans | PharmD Ching-Hon Pui | MD Meenakshi Devidas | PhD W. P. Bowman | MD Bruce M. Camitta | MD Cheryl L. Willman | MD Stella M. Davies | PhD Michael J. Borowitz | PhD William L. Carroll | MD Stephen P. Hunger | MD Mary V. Relling | PhD Jun J. Yang | PhD Cheng Cheng | PhD Wenjian Yang | MS Deqing Pei | MS Xueyuan Cao | PhD Yiping Fan | PhD Stanley B. Pounds | PhD Geoffrey Neale | PhD Lisa R. Trevin˜o | PhD Deborah French | MD Dario Campana | PhD James R. Downing | PharmD Ching-Hon Pui | PhD W. P. Bowman | MD Bruce M. Camitta | MD Cheryl L. Willman | PhD Michael J. Borowitz | PhD William L. Carroll | MD Stephen P. Hunger
[1] Peter W. Swaan,et al. Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids , 2003, Pharmaceutical Research.
[2] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.
[3] Cheng Cheng,et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. , 2006, Blood.
[4] M. Schrappe,et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.
[5] R. Collins,et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.
[6] B. Sikic,et al. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. , 1992, Cancer research.
[7] K. Ness,et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. , 2003, JAMA.
[8] C. Pui,et al. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia , 2007, Nature Reviews Drug Discovery.
[9] M. Relling,et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.
[10] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[11] C. Gieger,et al. Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.
[12] W. Kamps,et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia , 2003, Clinical pharmacology and therapeutics.
[13] M. Krajinovic,et al. Polymorphisms in Genes Involved in the Corticosteroid Response and the Outcome of Childhood Acute Lymphoblastic Leukemia , 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[14] M. Relling,et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.
[15] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[16] S. Armstrong,et al. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. , 2005, Blood.
[17] B. Schäfer,et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.
[18] Dong-Joon Min,et al. Childhood acute lymphoblastic leukemia in the age of genomics , 2006, Pediatric blood & cancer.
[19] J J Shuster,et al. Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study , 2003, Leukemia.
[20] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[21] Dan M Roden,et al. Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.
[22] Paul Scheet,et al. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. , 2006, American journal of human genetics.
[23] A Hofman,et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.
[24] B. Bostrom,et al. Systemic Methotrexate Exposure Is Greater After Intrathecal Than After Oral Administration , 2003, Journal of pediatric hematology/oncology.
[25] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[26] R. Paus,et al. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. , 2006, Cytokine & growth factor reviews.
[27] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[28] D L Sackett,et al. An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.
[29] H. Schünemann,et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Cheng Cheng,et al. Statistical Significance Threshold Criteria For Analysis of Microarray Gene Expression Data , 2004, Statistical applications in genetics and molecular biology.
[31] M. Relling,et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Bleyer Wa,et al. Accumulation of methotrexate in systemic Tissues after intrathecal administration , 1997 .
[33] J. Downing,et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. , 2005, The Journal of clinical investigation.
[34] Cheng Cheng,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.
[35] M. Relling,et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.
[36] R. Greil,et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. , 2000, Blood.
[37] J. Gribben,et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. , 2007, Blood.
[38] Cheng Cheng,et al. In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile , 2008, PLoS medicine.
[39] Nathaniel Rothman,et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.
[40] Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .
[41] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[42] Peter Kraft,et al. Drinking from the fire hose--statistical issues in genomewide association studies. , 2007, The New England journal of medicine.
[43] Terence P. Speed,et al. Genome analysis A genotype calling algorithm for affymetrix SNP arrays , 2005 .
[44] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[45] M. Relling,et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.
[46] J. Downing,et al. Results of therapy for acute lymphoblastic leukemia in black and white children. , 2003, JAMA.
[47] N. Schork,et al. Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. , 2008, American journal of human genetics.
[48] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[49] W. Carroll. Race and outcome in childhood acute lymphoblastic leukemia. , 2003, JAMA.
[50] A. Hofman,et al. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. , 2008, American journal of human genetics.
[51] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[52] M. Loh,et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.
[53] J. Downing,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[54] E. Cook,et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. , 2004, Blood.
[55] E. Cook,et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.
[56] E. Cook,et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. , 2007, Blood.
[57] J. Beijnen,et al. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[58] Jin‐ding Huang,et al. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption , 2009, Cancer Chemotherapy and Pharmacology.
[59] G. Galbraith. Polymorphisms in Interleukin-15 Gene on Chromosome 4q31.2 Are Associated with Psoriasis Vulgaris in Chinese Population , 2008 .
[60] M. Caligiuri,et al. Interleukin 15: biology and relevance to human disease. , 2001, Blood.
[61] Jiang Xue-qiang. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 2010 .
[62] E. Cook,et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.
[63] P. Neuvonen,et al. Cytochrome P450‐inducing antiepileptics increase the clearance of vincristine in patients with brain tumors , 1999, Clinical pharmacology and therapeutics.
[64] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[65] M. McCarthy,et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.
[66] G. Basso,et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] R. Crazzolara,et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. , 2006, Blood.
[68] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.